Bronchopulmonary Dysplasia
Conditions
Keywords
bronchopulmonary dysplasia, clarithromycin, preterm babies
Brief summary
The purpose of this study is to determine of clarithromycin effect on developing of bronchopulmonary dysplasia in preterm babies.
Detailed description
The investigators planned that clarithromycin treatment in preterm babies who are under 1250 grams birth weight. The investigators aimed with this treatment, the bronchopulmonary dysplasia rate of preterm babies may decrease.
Interventions
DRUGclarithromycin treatment for prophylaxis of bronchopulmonary dysplasia
DRUGSaline
Sponsors
Zekai Tahir Burak Women's Health Research and Education Hospital
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
SINGLE (Caregiver)
Eligibility
Sex/Gender
ALL
Age
1 Hours to 2 Days
Healthy volunteers
No
Inclusion criteria
* all infant must be under 1250 gram birth weight
Exclusion criteria
* Major congenital anomaly, * CardiaC abnormality, * without inform consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Bronchopulmonary dysplasia | 28. day of birth | On the 28. day of birth, The investigator will determine the baby whether has developed bronchopulmonary dysplasia |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | Participants will be followed for the duration of hospital stay, an expected average of postnatal 40 weeks | During to hospitalisation the investigator will determine and record some co-morbidities of BPD such as intracranial hemorrhage, necrotizing enterocolitis, patent ductus arteriosus rates.From date of randomization until the end of the hospitalisation up to the 3 months of life. |
Countries
Turkey (Türkiye)
Contacts
Primary ContactSadık Yurttutan, M.D
Backup ContactFuat Emre Canpolat, M.D.
Outcome results
None listed